Cancer Medicine (Jun 2023)

A nurse‐led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study

  • Lisa Scarton,
  • Tarah Nelson,
  • Ara Jo,
  • LaToya J. O’Neal,
  • Yingwei Yao,
  • Shavondra Huggins,
  • Anatolia B. Legaspi,
  • Mariah J. McClaren,
  • Jake S. Cabassa,
  • Joan M. Burgos Melendez,
  • Juan M. Munoz‐Pena,
  • Merry J. Markham,
  • Martina C. Murphy,
  • Jonathan A. Chatzkel,
  • Sherise Rogers,
  • Thomas J. George

DOI
https://doi.org/10.1002/cam4.6118
Journal volume & issue
Vol. 12, no. 11
pp. 12874 – 12880

Abstract

Read online

Abstract Background Undiagnosed Type 2 diabetes (T2D) has been associated with advanced stage cancer at diagnosis, higher mortality, and lower long‐term all‐cause survival. This was a RCT pilot study to examine the feasibility of a nurse‐led T2D intervention for adults with newly diagnosed cancer (≤3 months), and T2D, undiagnosed or untreated with medication, conducted at an outpatient oncology clinic affiliated with a large academic institution. Methods Participants needed to meet the eligibility criteria including a HbA1c level between 6.5% and 9.9%. Randomization was 1:1 to a 3‐month intervention that consisted of nursing‐led diabetes education and immediate initiation of metformin versus referral to primary care for usual care (control). Results Three hundred and seventy nine patients were screened using EHR, 55 agreed to participate, and 3 had eligible HbA1c levels and were randomized in the study. Primary reasons for study exclusion included life expectancy ≤2 years (16.9%), current use or inability to tolerate metformin (14.8%), and abnormal labs that contraindicated metformin use (13.9%). Conclusion This study was not feasible due to recruitment inefficiencies, but acceptable to all who qualified.

Keywords